George Addona, incoming SVP in charge of discovery, preclinical and translational work at Merck
As Fiona Marshall makes her move to NIBR, Merck is ready with a key replacement player
Just hours after Novartis flagged a big change at the top of NIBR — with Jay Bradner exiting and offering his post on the executive committee …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
